Abiraterone Accord الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Mylan الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Aderolio 0.25 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

aderolio 0.25 mg tabletti

sandoz a/s - everolimuusi - tabletti - 0.25 mg - everolimuusi

Aderolio 0.5 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

aderolio 0.5 mg tabletti

sandoz a/s - everolimuusi - tabletti - 0.5 mg - everolimuusi

Aderolio 0.75 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

aderolio 0.75 mg tabletti

sandoz a/s - everolimuusi - tabletti - 0.75 mg - everolimuusi

Aderolio 1 mg tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

aderolio 1 mg tabletti

sandoz a/s - everolimuusi - tabletti - 1 mg - everolimuusi

Abirateron Sandoz 500 mg tabletti, kalvopäällysteinen فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

abirateron sandoz 500 mg tabletti, kalvopäällysteinen

sandoz a/s - abiraterone acetate - tabletti, kalvopäällysteinen - 500 mg - abirateroni

Certican 0.25 mg dispergoituva tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

certican 0.25 mg dispergoituva tabletti

novartis finland oy - everolimuusi - dispergoituva tabletti - 0.25 mg - everolimuusi

Certican 0.1 mg dispergoituva tabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

certican 0.1 mg dispergoituva tabletti

novartis finland oy - everolimuusi - dispergoituva tabletti - 0.1 mg - everolimuusi